Table 2.
Healthcare resource use during study follow-up
| Outcome | Total | ICS versus non-ICS | ||||
|---|---|---|---|---|---|---|
| Adjusted | Unadjusted | |||||
| ICS | Non-ICS | Relative rate (95% CI) | P value* | Relative rate (95% CI) | P value* | |
| Short-acting therapy prescriptions | 24,063 | 21,163 | 1.05 (0.97–1.14) | 0.212 | 1.09 (1.01–1.18) | 0.026 |
| All-cause interactions | ||||||
| All HCP | 72,802 | 69,136 | 1.07 (1.00–1.14) | 0.061 | 1.05 (0.98–1.13) | 0.156 |
| GP | 55,927 | 52,947 | 1.07 (1.00–1.14) | 0.063 | 1.06 (0.98–1.13) | 0.129 |
| Outpatient | 13,497 | 12,989 | 1.01 (0.94–1.08) | 0.802 | 1.04 (0.93–1.16) | 0.485 |
| Hospital | 3378 | 3200 | 1.05 (0.93–1.19) | 0.434 | 1.06 (0.94–1.19) | 0.377 |
| Respiratory-related interactions | ||||||
| All HCPa | 20,555 | 19,543 | 1.04 (0.98–1.12) | 0.209 | 1.05 (0.98–1.13) | 0.154 |
| Routine GP | 16,391 | 15,409 | 1.05 (0.99–1.13) | 0.127 | 1.06 (0.99–1.14) | 0.078 |
| Unplanned GP | 2166 | 2085 | 1.04 (0.92–1.18) | 0.506 | 1.04 (0.92–1.17) | 0.530 |
| Outpatient | 247 | 234 | 1.04 (0.78–1.39) | 0.809 | 1.06 (0.80–1.40) | 0.705 |
| Hospital | 1751 | 1815 | 0.95 (0.83–1.09) | 0.465 | 0.96 (0.84–1.10) | 0.603 |
*Significant at α = 0.05; aGP + outpatient + hospital
CI confidence interval, GP general practitioner, HCP healthcare practitioner, ICS inhaled corticosteroid